SUZHOU, China – At the Chinabio Partnering Forum, a panel of leading Chinese biopharma founders and executives discussed the future of immuno-oncology in China to a packed room in Suzhou, a biotech hub a short distance from Shanghai. The speakers were cautiously optimistic about China's future in this hot new category of cancer treatment, artfully skirting around direct mention of the government's recent ban on immunotherapy following a scandal involving a patient who died after receiving DC-CIK treatment. (See BioWorld Today, May 10, 2016.)